Shots:

• The P-III global programme involves assessing of Roxadustat vs PBO & epoetin alfa in 9-000+ patients with anemia + CKD not on dialysis (NDD) - dialysis-dependent (DD)- ID respectively
• Pooled analyses results: MACE/MACE+ in NDD & DD patients- clinically no difference; MACE/MACE+ in ID patients shows better results
• Roxadustat is hypoxia-inducible-factor prolyl hydroxylase inhibitor- evaluated under the collaboration of AstraZeneca- FibroGen and Astellas with its expected FDA’s regulatory submission in H2’19

Click here to read full press release/ article 

Ref: AstraZeneca | Image: AstraZeneca